Drug Discovery World

AUGUST 7, 2023

The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Susmita Sahoo, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai has been exploring the use of exosomes in gene therapy for several years.

Gene Therapy 52

Gene Therapy Gene Research In-Vivo 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

The most advanced programme of the company is adeno-associated virus (AAV)-based gene therapy, REN-001. It leverages gene transfer technology to target the monogenic cause of BAG3-linked dilated cardiomyopathy (DCM), a severe kind of heart failure. .

Gene Therapy 147

Gene Therapy Gene Cardiology Genetics 147

Scienmag

JANUARY 28, 2021

— In a new study published in Circulation, Mayo Clinic researchers provide the first preclinical, proof-of-concept study for hybrid gene therapy in long QT syndrome, a potentially lethal heart rhythm condition. ROCHESTER, Minn.

Gene Therapy 74

Gene Therapy Gene In-Vitro Clinical Research 74

STAT News

JANUARY 6, 2023

… Pfizer told employees it plans to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies , Barron’s reports. Among the assets on the chopping block is a gene therapy manufacturing facility in Durham, N.C.,

Gene Therapy 98

Gene Therapy Trials Research Cardiology 98

STAT News

JULY 12, 2022

Somewhere in New Zealand, the first patient ever has been dosed with a kind of gene-editing treatment known as a base editor, a newer way of utilizing CRISPR for gene editing. The company studying the treatment, Verve Therapeutics, announced the news Tuesday. Continue to STAT+ to read the full story…

Gene Editing 98

Gene Editing Gene Therapy Gene Cardiology 98

Drug Discovery World

NOVEMBER 17, 2023

Asklepios BioPharmaceutical (AskBio), a gene therapy subsidiary of Bayer, has presented first-in-human data from a Phase I trial investigating AB-1002 (also known as NAN-101) for the treatment of patients with congestive heart failure (CHF).

Gene Therapy 105

Gene Therapy Gene Cardiology Trials 105

XTalks

FEBRUARY 16, 2024

Related: Vyjuvek Gets FDA Nod as First Topical Gene Therapy for Rare Skin Disease The active ingredient in Aurlumyn is iloprost, a vasodilator that opens up blood vessels and stops blood from clotting. Blisters, which can affect all layers of skin, typically form 24 hours after exposure and tissue turns black if it starts dying.

Cardiology 59

Cardiology Gene Therapy Drugs Branding 59